Use of 18FDG-PET imaging to predict treatment response to IGF-1R/IR targeted therapy in lung cancer

Abstract

The use of 18FDG-PET imaging to predict treatment response to IGF-1R/IR targeted therapy in mouse models of human lung cancer is presented in this thesis. In vitro cell studies were first conducted to establish sensitivity to treatment with OSI-906 and changes in glucose metabolism in responding cells. In vivo xenograft studies demonstrated that reduced 18FDG-PET correlated with PI3K pathway inhibition and was able to predict tumor response to OSI-906 prior to changes in tumor volume could be ascertained. The in vivo imaging results were validated with molecular correlates. Based upon these results 18FDG-PET imaging appears to serve as a rapid non-invasive marker of IGF-1R/IR inhibition and should be explored clinically as a predictive clinical biomarker in patients undergoing IGF-1R/IR-directed cancer therapy.